Stockscreener 앱 받기
4.43
3.49%
-0.16
전일 마감가:
$4.59
열려 있는:
$4.6
하루 거래량:
25,758
Relative Volume:
0.35
시가총액:
$73.69M
수익:
-
순이익/손실:
$-23.87M
주가수익비율:
-0.2252
EPS:
-19.67
순현금흐름:
$-47.63M
1주 성능:
-1.99%
1개월 성능:
+0.45%
6개월 성능:
+26.93%
1년 성능:
+56.48%
1일 변동 폭
$4.3795
$4.60
1주일 범위
$4.3501
$4.77
52주 변동 폭
$2.30
$5.12
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.43 | 76.35M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
Research Analysts Issue Forecasts for PolyPid Q1 Earnings - Defense World
HC Wainwright Predicts PolyPid's Q1 Earnings (NASDAQ:PYPD) - MarketBeat
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? - Yahoo Finance
PolyPid Q4 Earnings Call Highlights - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 Earnings Call Transcript - Insider Monkey
Is PolyPid Ltd. likely to announce a buybackJuly 2025 Recap & Low Risk High Win Rate Picks - mfd.ru
FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright - MarketBeat
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced US partnership talks - MSN
PolyPid Earnings Call Flags Big 2026 Catalyst - TipRanks
PolyPid (PYPD) Analyst Rating Reiteration by HC Wainwright | PYP - GuruFocus
PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright - MarketBeat
PolyPid (NASDAQ:PYPD) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts - Investing.com India
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances U.S. Partnership Talks for D-PLEX₁₀₀ Following Positive FDA Feedback and Plans Rolling NDA Review - Quiver Quantitative
Preview: PolyPid's Earnings - Benzinga
Will PolyPid Ltd. stock recover after earnings2025 AllTime Highs & Capital Protection Trade Alerts - mfd.ru
Aug Closing: Is PolyPid Ltd likely to announce a buybackMarket Activity Summary & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Decrease in Short Interest - MarketBeat
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 - The Manila Times
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will PolyPid Gain Momentum Ahead Of Its NDA Filing? - RTTNews
Rate Hike: Will VF Corporation announce a stock splitWeekly Trade Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Aug Movers: Is AAME forming bullish engulfing patternsEarnings Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Aug Movers: Will PolyPid Ltd stock recover after earnings2025 Technical Overview & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid calls February 2026 extraordinary meeting to approve board chair compensation - MSN
Aug Sentiment: Is PolyPid Ltd stock technically oversoldJuly 2025 Institutional & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
PYPD: D-PLEX 100's phase 3 success paves the way for FDA submission and U.S. commercialization - TradingView
Aug Catalysts: Will PolyPid Ltd stock return to pre crisis levels2025 Buyback Activity & Low Risk High Win Rate Picks - Bộ Nội Vụ
Why analysts remain bullish on PolyPid Ltd. stockQuarterly Risk Review & High Conviction Buy Zone Alerts - Улправда
Aug Big Picture: Can PolyPid Ltd. stock hit analyst price targetsJuly 2025 Earnings & Intraday High Probability Setup Alerts - Улправда
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Why PolyPid Ltd. stock could see breakout soonQuarterly Trade Review & Comprehensive Market Scan Insights - Улправда
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Polypid names medtech veteran Brooke Story as board chairman - marketscreener.com
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
PolyPid (PYPD) appoints medtech veteran Brooke Story as board chairman - Stock Titan
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - marketscreener.com
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):